Houlihan Financial Resource Group’s Trillium Therapeutics Inc. TRIL Stock Holding History

Houlihan Financial Resource Group’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$6K	Buy	+413	New	+$4.12K	﹤0.01%	297

Other funds holding TRIL

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Citadel Advisors

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Franklin Resources

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Houlihan Financial Resource Group's TRIL Position: Q3 2020 in Review

Houlihan Financial Resource Group opened a new position in Trillium Therapeutics Inc. (TRIL) in Q3 2020: 413 shares worth $6K. The stake represents ﹤0.01% of the portfolio and ranks #297 among its holdings.

114 funds tracked by Wall St. Rank hold TRIL as of Q3 2020.

Houlihan Financial Resource Group held 413 shares of Trillium Therapeutics Inc. worth $6K as of Q3 2020.
Trillium Therapeutics Inc. was a new Houlihan Financial Resource Group position in Q3 2020.
Trillium Therapeutics Inc. made up ﹤0.01% of Houlihan Financial Resource Group's portfolio in Q3 2020, its #297 holding.
114 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q3 2020.

Based on Houlihan Financial Resource Group's 13F filing for Q3 2020, filed 13 Nov 2020.